以上来源于: WordNet
Biotechnology companies spend years figuring out the right combination of mutant host organism and reactor conditions to fashion a protein therapy that is safe and effective.
生物科技公司耗费数年时间,试著找出适当的突变宿主生物与反应环境组合,以得到安全有效的蛋白质治疗方法。
Therefore, inhibiting polyglutamine protein aggregation or deposition would be an important target for HD therapy.
多聚谷氨酰氨的聚集、沉淀可能是该病发病的原因和关键。
This fall, the startup company Tivorsan Pharmaceuticals licensed rights from Brown to the key protein, biglycan, hoping to bring the potential therapy through clinical trials.
今年秋天,新兴的生物制药公司Tivorsan已经从布朗大学得到了这种关键蛋白biglycan的生产许可权,希望能将这种潜在的新疗法带入临床试验阶段。
应用推荐